Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix in Castrate Resistant Prostate Cancer
NCT01630967Phase 2Withdrawn
- Sponsor
- BC Cancer
- Start
- Aug 2012
- Primary completion
- Dec 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of degarelix in castration-resistant prostate cancer (CRPC), sponsored by BC Cancer. Planned start Aug 2012; status: withdrawn.
02
Drugs
degarelix
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01630967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630967.